Dianthus Therapeutics, Inc. (DNTH)

Market Cap	606.22M
Revenue (ttm)	6.52M
Net Income (ttm)	-100.73M
Shares Out	32.16M
EPS (ttm)	-2.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	101,602
Open	18.42
Previous Close	18.38
Day's Range	18.11 - 19.02
52-Week Range	13.37 - 32.27
Beta	n/a
Analysts	Strong Buy
Price Target	53.00 (+181.17%)
Earnings Date	Aug 7, 2025

About DNTH

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company’s lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 78
• Stock Exchange: NASDAQ
• Ticker Symbol: DNTH
• Website: https://dianthustx.com

Financial Performance

In 2024, Dianthus Therapeutics's revenue was $6.24 million, an increase of 120.63% compared to the previous year's $2.83 million. Losses were -$84.97 million, 95.1% more than in 2023.

Analyst Summary

According to 8 analysts, the average rating for DNTH stock is "Strong Buy." The 12-month stock price target is $53.0, which is an increase of 181.17% from the latest price.

Price Target

$53.0

(181.17% upside)

Analyst Consensus: Strong Buy